Intercept Pharmaceuticals Inc ICPT:NASDAQ

RT Quote | NASDAQ | USD
Last | 08/08/22 EDT
16.85quote price arrow up+0.43 (+2.62%)
Volume
707,387
52 week range
10.81 - 20.50
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close16.85
  • 52 Week High20.50
  • 52 Week High Date11/03/21
  • 52 Week Low10.81
  • 52 Week Low Date06/16/22

Key Stats

  • Market Cap502.13M
  • Shares Out29.80M
  • 10 Day Average Volume1.07M
  • Dividend-
  • Dividend Yield-
  • Beta1.23
  • YTD % Change3.44

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close16.85
  • 52 Week High20.50
  • 52 Week High Date11/03/21
  • 52 Week Low10.81
  • 52 Week Low Date06/16/22
  • Market Cap502.13M
  • Shares Out29.80M
  • 10 Day Average Volume1.07M
  • Dividend-
  • Dividend Yield-
  • Beta1.23
  • YTD % Change3.44

RATIOS/PROFITABILITY

  • EPS (TTM)-3.15
  • P/E (TTM)-5.35
  • Fwd P/E (NTM)7.27
  • EBITDA (TTM)-65.531M
  • ROE (TTM)-143,254.90%
  • Revenue (TTM)316.13M
  • Gross Margin (TTM)99.30%
  • Net Margin (TTM)-29.63%
  • Debt To Equity (MRQ)-193.02%

EVENTS

  • Earnings Date11/01/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Intercept Pharmaceuticals Inc

There is no recent news for this security.

Profile

MORE
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company’s marketed product, Ocaliva, is a farnesoid X receptor (FXR)...
Paolo Fundaro
Independent Chairman of the Board
Jerome Durso
President, Chief Executive Officer, Director
Andrew Saik
Chief Financial Officer
Rocco Venezia
Chief Accounting Officer
Jared Freedberg
General Counsel
Address
305 Madison Avenue
Morristown, NJ
07960
United States

Top Peers

SYMBOLLASTCHG%CHG
AGEN
Agenus Inc
2.61-0.04-1.51%
MDXG
MiMedx Group Inc
4.19+0.25+6.35%
KPTI
Karyopharm Therapeutics Inc
5.16+0.48+10.26%
NVTA
Invitae Corp
2.52+0.22+9.57%
AKBA
Akebia Therapeutics Inc
0.405+0.01+2.53%